Page 1

Exscientia Business Update for Third Quarter 2021 OXFORD , U.K. - Exscientia ( Nasdaq : EXAI ) Recent advancements in the Company's pipeline , collaborations and operations as well as financial results for the third quarter ended September 30 , 2021 are summarised below . In addition , Exscientia will host a conference call on Thursday , November 18 at 1:30 p.m. GMT / 8:30 a.m. ET to provide detail on the business models underlying the Company's pipeline of more than 25 programmes . Highlights Leveraging deep learning on patient tissue samples at scale to transform target discovery and patient selection - Expanded investigation of patient tissue models in solid tumours , including ongoing analysis of EXS - 617 in ovarian and breast cancer models Published EXALT - 1 clinical trial results in Cancer Discovery that highlighted benefit of the first Al - supported functional precision medicine platform to guide treatment selection and improve outcomes in patients with advanced haematological cancer Completed acquisition of Allcyte , integrating leading tissue platform into Exscientia's end - to- end drug discovery operations Pipeline progress marked by candidate nomination , significant expansion of existing collaborations Partnered programmes Expanded Bristol Myers Squibb collaboration to include potential targets across immunology and oncology ; potential deal value beyond $ 1.3 billion BMS in - licensed first candidate from original 2019 collaboration , a potential first - in - class immunology medicine , triggering $ 20.0 million option exercise fee Co - owned programmes ○ EXS - 617 : development candidate nominated for CDK7 inhibitor from expanded joint venture with GT Apeiron ; additional translational data anticipated 1H 2022 о First two targets selected in EQRX joint venture Wholly and majority owned programmes о EXS - 21546 : Phase 1 data for A2a antagonist in high adenosine signature cancers expected 1H 2022 ; translational research programmes for patient selection ongoing Entered into third collaboration with Bill & Melinda Gates Foundation that added portfolio of up to five antiviral small molecule drug candidates and accelerated development of SARS - CoV - 2 lead programme Strengthened balance sheet providing several years of cash runway to deliver Al - designed molecules and accelerate pipeline growth Expect between $ 75.0- $ 85.0 million in cash inflows from collaborations for full year 2021 In October , closed $ 510.4 million gross aggregate financing , consisting of $ 350.4 million gross proceeds from upsized initial public offering and $ 160.0 million gross proceeds from concurrent private placement Cash at the end of the third quarter 2021 , adjusted to include the net proceeds from the initial public offering completed on October 5 , 2021 , was $ 783.7 million Expanding drug discovery and automation laboratories to scale capacity and operations Opened 21,000 - square foot expansion of facilities at Oxford Science Park